Loading
A phase 1/2 trial of Verteporfin in prostate cancer, run by SpectraCure AB, now recruiting.
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System is a phase 1/2 interventional study registered as NCT03067051 by SpectraCure AB, with 66 participants planned, started 2017-03-21 and due to reach its primary completion in 2027-07-31. Interventions recorded: Verteporfin and SpectraCure P18 System.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SpectraCure, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/